| 325) rofile followed by 2 weeks of either Epi treatment at 1 mg/kg/day by gavage (n = |
| 326) veloped for evaluating only one candidate treatment at a time, and are thus not opti |
| 327) he Bayesian posterior probability of each treatment being optimal. |
| 328) HNC) are diagnosed worldwide with primary treatment being surgery and radiotherapy. |
| 329) The average difference in post-treatment compared to pre-treatment non-HD |
| 330) high Drug Burden Index (DBI) polypharmacy treatment compared to control on physical |
| 331) on administration, hygiene and isolation, treatment decisions, or invasive procedure |
| 332) To improve dengue triage and treatment decisions, the WHO recommends cl |
| 333) aying reward responsiveness to accelerate treatment development for neuropsychiatric |
| 334) ions and laboratory animals, which hamper treatment development. |
| 335) Moreover, statin treatment did not reduce the number of flo |
| 336) Importantly, statin treatment did not reverse d-flow-regulated |
| 337) Treatment dose (amount of treatment) has b |
| 338) or post-stroke aphasia and to explore how treatment dose is conceptualized, measured |
| 339) approach to alleviate liver fibrosis, and treatment efficacy can be monitored by obs |
| 340) ould very likely be necessary to maintain treatment efficacy. |
| 341) The use of specific clinical treatment goals (e.g., two-hour pain free |
| 342) iol doses ≥ 1.5 mcg/day to meet current treatment goals. |
| 343) ificant main effect in the high vitamin D treatment group in VDAART. |
| 344) Studies were included if they had a treatment group with a mean age of 65 year |
| 345) ties are different or the sample sizes of treatment groups are unbalanced. |
| 346) ion of unbalanced sample sizes in the two treatment groups or large treatment effect |
| 347) entlessly for the single most efficacious treatment may indirectly diminish the numb |
| 348) lts suggest that long-term PARP inhibitor treatment may prime both BRCA1 mutant and |
| 349) is that readers may focus overly on what treatment ranks best and focus insufficien |
| 350) or to compare the intervals or ranges of treatment ranks. |
| 351) Mechanistically, adropin treatment reduced BBB damage, degradation |
| 352) No studies showed that antifungal treatment reduced mortality. |
| 353) m regulator of cell fate, plasticity, and treatment resistance in NEPC that can rev |
| 354) etect rare subclones possibly involved in treatment resistance. |
| 355) tential to help in prevention, diagnosis, treatment, screening, management, and cont |
| 356) demics in terms of prevention, diagnosis, treatment, screening, surveillance, resour |
| 357) may influence the future of brain injury treatment through modulation of neuroinfla |
| |